Schapira / Hartmann / Agid Parkinsonian Disorders in Clinical Practice

1. Auflage 2009
ISBN: 978-1-4443-0639-2
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 208 Seiten, E-Book

This book gives the reader an up-to-date, clear and logical idea ofwhat caring for parkinsonian patients entails - a challenge thatclinicians will face for many years to come. It is split into threesections:
Section 1: A compilation of the major brain lesions typicallyseen in PD
Section 2: Treatment options in PD
Section 3: 25 cases designed to test the reader and thepractical application of the information supplied in the othersections.

Autoren/Hrsg.

Schapira, Anthony

Hartmann, Andreas

Agid, Yves

Inhaltsverzeichnis

Preface.
Introduction.
1 What is Parkinson's disease? From pathophysiologyto symptoms (Andreas Hartmann, Yves Agid, AnthonySchapira).
I. Pathophysiology of Parkinson's disease.
1. Dysfunctions of the main neuronal pathways inParkinson's disease.
a. An overview of neuronal systems affected in Parkinson'sdisease.
b. Dopaminergic neurons.
c. Non-dopaminergic neurons.
2. Consequences of dopaminergic neuronal lesions on basalganglia circuits.
a. The dopaminergic nigrostriatal system: pre- and postsynapticcompensatory mechanisms.
b. Pathologic alterations of nigrostriatal circuits inParkinson's disease.
3. Histopathology of Parkinson's disease.
4. The etiopathogenesis of Parkinson's disease.
a. The genetics of Parkinson's disease: any clues for thesporadic forms?
b. Relevant environmental factors: focus on mitochondria.
c. Mechanisms of cell death in Parkinson's disease:therapeutic implications.
5. Conclusions.
a. Parkinson's disease or Parkinson's syndromes?
b. What Parkinson's disease is not.
II. Clinical features of Parkinson's disease.
1. Motor symptoms.
2. Non-motor symptoms.
a. Depression.
b. Apathy.
c. Cognitive impairment.
d. Sleep.
e. Autonomic dysfunction.
f. Sensory symptoms.
3. The different forms of Parkinson's disease: relevancefor prognosis.
4. The differential diagnosis of Parkinson's disease.
5. Treatment-related symptoms.
a. Motor complications.
b. Non-motor complications.
2 Treatment of Parkinson's disease (AnthonySchapira, Andreas Hartmann, Yves Agid).
I. Antiparkinsonian agents.
1. Levodopa.
2. COMT inhibitors.
3. Dopamine agonists.
4. Monoamine oxidase B inhibitors.
5. Other drugs.
II. Medical management.
1. Initiation of treatment.
2. Maintenance of treatment (Fig. 2.7).
3. Motor complications.
4. Management of non-motor complications.
III. Non-medical management.
1. Surgery.
2. Destructive lesions.
3. Cell therapy.
4. Growth factors.
IV. Neuroprotection.
1. MAO-B inhibitors.
2. Dopamine agonists.
3. Coenzyme Q.
4. Creatine.
5. Antiapoptotic drugs.
V. Conclusion.
3 Case studies.
Case studies--diagnostic index.
Index.

Über Autor(innen)

Anthony HV Schapira, MD DSC, FRCP, FMedSci, Professor and Head of Department University College of Clinical Neurosciences, Institute of Neurology, University College London, Queen Square, London UK. Professor of Neurology, National Hospital for Neurology and Neurosurgery and Roayl Free Hospital, London, UK.

Andreas Hartmann, MD, Clinical Investigation Center, Pitie-Salpetriere Hopital, Paris, France. Federation of Nervous System Disease, Pitie-Salpetriere Hopital, Paris, France. National Institute of Health and Medical Research, Paris, France. Pierre and MAric Curie University,?Paris, France.

Yves Agid, MD, PhD, Clinical Investigation Center, Pitie-Salpetriere Hopital, Paris, France. Federation of Nervous System Disease, Pitie-Salpetriere Hopital, Paris, France. National Institute of Health and Medical Research, Paris, France. Pierre and MAric Curie University,?Paris, France.